Picture of InMode logo

INMD — InMode News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapSuper Stock

InMode Q2 revenue misses estimates

Overview

InMode Q2 revenue rises to $95.6 mln, missing analyst expectations

EPS for Q2 meets analyst expectations at $0.42 per share

Co's international sales offset U.S. market challenges

Outlook

Company anticipates full-year non-GAAP EPS of $1.55 to $1.59

InMode expects 2025 non-GAAP income from operations of $93 mln to $98 mln

Company cites macroeconomic uncertainty and cautious consumer behavior as headwinds

Result Drivers

MACROECONOMIC UNCERTAINTY - Co cites ongoing macroeconomic uncertainty and cautious consumer behavior impacting Q2 results

INTERNATIONAL SALES - Record high sales in Europe offset challenges in U.S. market, per CEO Moshe Mizrahy

TARIFF IMPACT - Potential 2% to 3% impact on gross margins due to U.S. tariffs, per CFO Yair Malca

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 RevenueMiss$95.60 mln$96.50 mln (7 Analysts)
Q2 EPSMeet$0.42$0.42 (7 Analysts)
Q2 Net IncomeMiss$26.74 mln$28.80 mln (4 Analysts)
Q2 Gross Margin80.0%
Q2 Pretax ProfitMiss$30.94 mln$32.10 mln (5 Analysts)
Q2 Operating Expenses$53.57 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell" The average consensus recommendation for the advanced medical equipment & technology peer group is "buy." Wall Street's median 12-month price target for Inmode Ltd is $16.00, about 10.6% above its July 29 closing price of $14.31 The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago Press Release: ID:nPn8JVtBHa (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on InMode

See all news